Chiesi Group acquires KalVista Pharmaceuticals

Viatris to Acquire Pacira BioSciences for $1.65 Billion

October 8, 2026

Pharmaceuticals

Viatris agreed to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, valuing the company at approximately $1.65 billion. The pending acquisition would expand Viatris’ innovative medicines business and strengthen its position in non-opioid pain management; closing is expected by the end of 2026, subject to customary conditions.

Amneal Pharmaceuticals Acquires Kashiv BioSciences to Build Global Biosimilars Platform

April 22, 2026

Healthcare Services

Amneal Pharmaceuticals entered into a definitive agreement to acquire 100% of Kashiv BioSciences in a deal with $375 million in cash and $375 million in equity at closing, plus up to $350 million in contingent regulatory milestone payments and potential commercial royalties. The acquisition is expected to close in the second half of 2026 and will create a fully integrated global biosimilars platform combining Kashiv’s development and manufacturing capabilities with Amneal’s commercial scale.

Novartis AG Acquires Chinook Therapeutics

June 12, 2023

Biotechnology

Novartis AG agreed to acquire Chinook Therapeutics for $40 per share in cash, with contingent value rights of up to $4 per share tied to regulatory milestones —bringing total consideration to as much as approximately $3.5 billion. The acquisition, approved by both companies' boards, brings Chinook's kidney-disease pipeline into Novartis' renal portfolio and was expected to close in the second half of 2023 subject to customary conditions.

Innoviva Acquires La Jolla Pharmaceutical Company

July 11, 2022

Pharmaceuticals

Innoviva entered into a definitive merger agreement to acquire La Jolla Pharmaceutical Company for $6.23 per share in cash (including a tender offer), representing an implied enterprise value of about $149 million. The acquisition adds GIAPREZA and XERAVA to Innoviva’s infectious disease and hospital portfolio and was completed in August 2022, with La Jolla becoming a wholly owned subsidiary and delisted from Nasdaq.

Alcon Acquires EYSUVIS and INVELTYS Commercial Portfolio from Kala Pharmaceuticals

May 23, 2022

Pharmaceuticals

Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.